Calluna Pharma’s Post

Innovating to tackle intractable diseases like idiopathic pulmonary fibrosis (IPF) motivates CEO Marc Hertz and B2i Digital’s featured company, GRI Bio, Inc. (NASDAQ: GRI). In this recent video, Hertz shares his vision for GRI’s future, highlighting: -IPF’s high unmet need is reflected in recent M&A activity, with room for novel approaches like GRI’s NKT targeting. -GRI plans to let forthcoming Phase 2 data dictate the next steps. Several options exist, including partnerships or internal advancement. -GRI’s deep preclinical pipeline. Hertz believes GRI’s pipeline could fuel organic growth for years, paired with NKT platform applicability across fibrotic diseases. With seasoned leadership and a novel immunology-focused pipeline, GRI takes a long-term, strategic view toward making a difference for patients. Visit LinkedIn to read about GRI’s experienced management team, including Marc Hertz, Vipin Kumar (Chaturvedi), Leanne Kelly, and Albert Agro. Reach out to GRI’s outstanding investor relations team, including Jenene Thomas and her colleagues at JTC IR. We also encourage you to visit GRI Bio's website to learn more about its pioneering pipeline and view the company’s comprehensive B2i Digital profile. GRI is an inspiring company to watch.  https://lnkd.in/e538WVw3 #biotech #pharma #healthtech #medtech #immunotherapy #inflammation #autoimmune #fibrosis #pulmonaryfibrosis #lupus #pipelines #clinicaltrials #biologics #biopharma #immunology #raredisease #orphandrugs #drugdevelopment #biomarkers #trialdata #milestones #catalysts #B2iDigital #GRIBio

Discover the Bright Future of TL1A: A Beacon of Hope for Patients with Ulcerative Colitis, Crohn's Disease, and Inflammatory Bowel Disease 🌟 👉 In the relentless pursuit of innovation in healthcare, TL1A emerges as a shining star, offering new hope to those afflicted with debilitating inflammatory bowel conditions. Pfizer's collaboration with Roivant Sciences to launch Vant, focusing on the TL1A monoclonal antibody RVT-3101, signifies a groundbreaking advance in the treatment landscape. This promising therapeutic, initially developed by Pfizer and now in a phase IIb study for ulcerative colitis, demonstrates the potential of TL1A-targeted therapies to revolutionize patient care. But why is TL1A capturing the attention of pharmaceutical giants and startups alike? TL1A, also known as Vascular Endothelial Growth Inhibitor (VEGI) and a member of the Tumor Necrosis Factor (TNF) superfamily, plays a crucial role in regulating immune responses and inflammation. By targeting TL1A, researchers aim to modulate the body's inflammatory processes, offering relief and improved quality of life for those suffering from ulcerative colitis, Crohn's disease, and inflammatory bowel disease. 👉 The journey of TL1A from a molecular target to a beacon of hope for patients underscores the importance of relentless research and innovation. With several TL1A monoclonal antibodies, including Prometheus Biosciences' PRA023 and Pfizer's RVT-3101, advancing through clinical trials, the future looks bright for those seeking new treatments for inflammatory bowel diseases. 👉 Stay updated on this transformative journey and explore how TL1A-targeted therapies could become a lifeline for patients. Visit our website at https://lnkd.in/gD9bYNgV for more information or reach out to us at 🙌 support@antibodysystem.com and order@antibodysystem.com 🙌 for inquiries and orders. #TL1A #InflammatoryBowelDisease #UlcerativeColitis #CrohnsDisease #HealthcareInnovation #Biotech #PharmaIndustry #AntibodySystem #RecombinantProteinsAndAntibodies

𝗕𝗶𝗼𝗴𝗲𝗻 𝗺𝗮𝗸𝗲𝘀 $𝟭.𝟭𝟱𝗕 𝗯𝘂𝘆 𝗳𝗼𝗿 𝗔𝗥𝗖𝗛'𝘀 𝗛𝗜-𝗕𝗶𝗼 𝘁𝗼 𝗲𝘅𝗽𝗮𝗻𝗱 𝗶𝗺𝗺𝘂𝗻𝗼𝗹𝗼𝗴𝘆 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 Biogen is further expanding beyond its neuroscience roots and dipping more into immunology with a $1.15 billion upfront acquisition of Human Immunology Biosciences, or HI-Bio. The Wednesday deal comes a few months after Biogen leadership said they’d do more early-stage licensing pacts and not splurge on M&A deals, of which they’ve only done one in recent years: a $7.3 billion consummation of commercial-stage rare disease drugmaker Reata Pharmaceuticals, Inc. Pharmaceuticals. https://lnkd.in/dgJmqcc9

⭐️ Inflammatory Target TSLP Thymic Stromal Lymphopoietin (TSLP) plays a key role in immune responses and is linked to various inflammatory diseases, making it a promising target for new therapies. 🔬 Key Insights: Functions: Critical in immune regulation and inflammation. Research Findings: Associated with allergic diseases, chronic inflammation, and cancer. Drug Developments: Includes Amgen and AstraZeneca's Tezepelumab, the first TSLP antibody drug, showing promising results for severe asthma without phenotype and biomarker restrictions. 💡 Kactus's Offerings: Supporting TSLP-related research with high-quality TSLP proteins for drug development covering various species and tag designs. Read the Full Blog Here 👉https://bit.ly/4cP9Ld1 #KACTUS #TSLP #Asthma #Protein #Biotech #Pharmaceuticals #Blog

Vol.18, 2024 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报 On June 13th, AbbVie made a $150 million upfront payment to FutureGen to introduce FG-M701, an antibody pipeline for treating IBD targeting TL1A. As a next-generation TL1A treatment solution, it offers better therapeutic efficacy and dosing frequency, and has the potential to become a Best-in-Class (BIC). TL1A, a very hot target over the past two years, saw Merck acquired Prometheus for $10.8 billion in 2023, while Roche introduced a TL1A pipeline incubated by Roivant for $7.1 billion. It is worth noting that TL1A is not the leading pipeline of FutureGen, and it is expected to enter clinical trials this year. AbbVie, with Humira, has a significant advantage in the IBD field. This transaction will be its strategy to cope with the patent cliff of Humira in IBD. Compared to TNFα, TL1A has higher specificity for IBD diseases. In addition to this target, others including RIPK1, SMAD7, Toll-like receptors, and microbiome therapies could potentially disrupt the current standard of care (SoC) in this field. #IBDTreatment #PharmaNews #Biotechnology https://lnkd.in/g8YHrTz6

Vol.18, 2024 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报 On June 13th, AbbVie made a $150 million upfront payment to FutureGen to introduce FG-M701, an antibody pipeline for treating IBD targeting TL1A. As a next-generation TL1A treatment solution, it offers better therapeutic efficacy and dosing frequency, and has the potential to become a Best-in-Class (BIC). TL1A, a very hot target over the past two years, saw Merck acquired Prometheus for $10.8 billion in 2023, while Roche introduced a TL1A pipeline incubated by Roivant for $7.1 billion. It is worth noting that TL1A is not the leading pipeline of FutureGen, and it is expected to enter clinical trials this year. AbbVie, with Humira, has a significant advantage in the IBD field. This transaction will be its strategy to cope with the patent cliff of Humira in IBD. Compared to TNFα, TL1A has higher specificity for IBD diseases. In addition to this target, others including RIPK1, SMAD7, Toll-like receptors, and microbiome therapies could potentially disrupt the current standard of care (SoC) in this field. #IBDTreatment #PharmaNews #Biotechnology https://lnkd.in/gQC26X7k

➰We are excited to invite you to a pivotal roundtable discussion on "Immune Dysregulation in Autoimmune Diseases and Cancers" led by the esteemed Rakesh Dixit, Co-founder, President, and CSO, Regio Biosciences taking place at the Immunotherapies Xchange, Maryland 2024.➰ RECEIVE YOUR COMPLIMENTARY REGISTRATION https://lnkd.in/ew_e8frR Key Discussion Points: ✔️Immune Homeostasis: Understanding the delicate balance through the interplay between the innate and adaptive immune systems. ✔️Immune Dysregulation in Cancers: Exploring the challenges and opportunities for advancing immunotherapy. ✔️Novel Immunotherapeutics: Innovations in treating autoimmune diseases and cancers. 💜This session is a must-attend for anyone involved in immunotherapy, oncology, and autoimmune disease research. Don’t miss this opportunity to gain insights from one of the industry's leading experts and network with peers.💜 🗣️ Rakesh brings over 35 years of ground-breaking experience from top biotechnology and pharmaceutical giants like Merck, Johnson & Johnson, and MedImmune - AstraZeneca. As a key industry expert, his contributions have earned him prestigious accolades including being named one of PharmaVOICE’s 100 Most Inspiring People and receiving the Long-Standing Contribution to ADCs Award by World ADC. 📅 Tuesday, 28th October 2024 🕒 15:40 - 16:40 📍 Marriott Hotel & Conference Centre Hyattsville, MD Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #Immunotherapy #AutoimmuneDiseases #CancerResearch #Biotech #Pharmaceuticals #ImmuneRegulation #ImmunotherapiesXchange2024 #HealthcareInnovation #Biologics #PharmaVOICE #WorldADC #ImmuneHomeostasis #AdaptiveImmunity #InnateImmunity #Immunotherapeutics #OncologyResearch #BiopharmaLeadership #ClinicalInnovation #TherapeuticDevelopment #MedicalBreakthroughs #IndustryInnovation #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

🧬 September 2024 Webinar on "RNA Manufacturing 101" 🧬 Excited for the next episode in #uBriGene’s Educational Live Webinar series? Join us for "RNA Manufacturing 101 - IVT Workflows for GMP Manufacturing" 🗓️ Date: September 26th, Thursday 🕛 Time: 12:00 PM EST 🎤 Presenter: Kenneth Warrington, Ph.D., Head of Technical Services Since Covid-19, #RNA_based_therapies, are advancing rapidly, impacting not just vaccine development but also expanding into treatments for various diseases. This webinar will cover the latest in RNA drug development and the pivotal role of in vitro transcription (IVT) in GMP manufacturing workflows. What You’ll Learn: - Basics of RNA drug development and the current landscape, including siRNA, sgRNA, #mRNA, circRNA, saRNA and more. - Overview of #GMP_manufacturing workflows for RNA therapies. - Key aspects of in-process and release testing panels. This session is ideal for professionals aiming to enhance their understanding of RNA manufacturing processes and ensure their workflows meet GMP standards. 🔗 Register now for free and secure your spot via https://lnkd.in/g-3at8mQ Don’t miss out—secure your place today and stay ahead in the fast-evolving world of RNA-based therapeutics! 🚀

Wondering how #vaccine innovation and the #pharmaceutical landscape have evolved since Covid-19, particularly with the rise of #RNA_based_therapies? Join #uBriGene's live webinar to dive into the intricacies of RNA manufacturing processes https://lnkd.in/g-3at8mQ

We are excited to announce that Hayley Wickens 𝗣𝗵𝗗 𝗙𝗙𝗥𝗣𝗦 𝗙𝗥𝗣𝗵𝗮𝗿𝗺𝗦, 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗶𝘀𝘁 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, 𝗡𝗛𝗦 𝗖𝗲𝗻𝘁𝗿𝗮𝗹 𝗮𝗻𝗱 𝗦𝗼𝘂𝘁𝗵 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 will be running a session entitled '𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲: 𝗧𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗴𝗲𝗻𝗼𝗺𝗶𝗰𝘀’ at the 𝗣𝗠 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗥𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗢𝗽𝘁𝗶𝗺𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗼𝗻 𝟵𝘁𝗵 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝗮𝘁 𝗕𝗖𝗘𝗖 𝗶𝗻 𝗕𝗶𝗿𝗺𝗶𝗻𝗴𝗵𝗮𝗺. Rapid advances in genomic sequencing technology over the last 20 years have started having an impact in healthcare. Applications range from precision genetic diagnosis e.g. cystic fibrosis, familial hypercholesterolaemia, through to gene therapies which ‘correct’ faulty versions of genes within patients, pathogen sequencing to track outbreaks and guide antimicrobial prescribing, and pharmacogenomics.  Pharmacogenomics uses patient DNA sequence to predict dosing requirements and efficacy of medicines, and risk of side effects, and is starting to be integrated into prescribing as part of the whole clinical picture. This session will explore what is already in place in the NHS and possible future directions; no previous genomics knowledge necessary! https://lnkd.in/gc-73sjY #PMHealthcare #advancingprecisionhealthcare #Pharmacy #pharmacogenomics